title: Effects of natriuretic peptides on load and myocardial function in normal and heart failure dogs.
abstract: The effects on myocardial function and loading conditions of clinically relevant doses of the natriuretic peptides (NP) have not been established. The actions of single doses (100 ng x kg(-1) x min(-1) iv over 30 min) of atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP) were studied in conscious normal dogs and in dogs with pacing-induced heart failure. All three NP reduced end-diastolic pressure in normal dogs, and ANP and BNP reduced end-diastolic volume. In heart failure ANP and BNP reduced EDP, and ANP reduced EDV. Arterial elastance was unchanged in normal dogs and in dogs with heart failure. ANP increased end-systolic elastance (E(es)) in normal dogs, whereas BNP tended to increase E(es) (P = 0.06). In dogs with heart failure, no inotropic effect was seen. In normal dogs, all NP reduced the time constant of isovolumic relaxation (tau), and ANP and BNP reduced tau in dogs with heart failure. Increases in plasma cGMP in dogs with heart failure were blunted. The NP reduced preload and enhanced systolic and diastolic function in normal dogs. Effects of ANP and BNP on preload and diastolic function were maintained in heart failure. Lack of negative inotropic effects in heart failure supports the validity of the NP as therapeutic agents.
authors.affiliation: Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic and Foundation, Rochester, Minnesota 55902, USA. lainchbury.john@mayo.edu
authors.forename: J G
authors.initials: JG
authors.lastname: Lainchbury
authors.forename: J C
authors.initials: JC
authors.lastname: Burnett
authors.forename: D
authors.initials: D
authors.lastname: Meyer
authors.forename: M M
authors.initials: MM
authors.lastname: Redfield
mesh_terms: D000818:Animals; D009320:Atrial Natriuretic Factor / Q000097:blood / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects*; D002303:Cardiac Output, Low / Q000503:physiopathology*; D006152:Cyclic GMP / Q000096:biosynthesis; D003971:Diastole; D004285:Dogs; D006321:Heart / Q000187:drug effects / Q000503:physiopathology*; D008297:Male; D009200:Myocardial Contraction / Q000187:drug effects; D009206:Myocardium / Q000378:metabolism; D020097:Natriuretic Peptide, Brain / Q000097:blood / Q000494:pharmacology*; D020098:Natriuretic Peptide, C-Type / Q000097:blood / Q000494:pharmacology*; D012016:Reference Values
chemical_list: D020097:Natriuretic Peptide, Brain; D020098:Natriuretic Peptide, C-Type; D009320:Atrial Natriuretic Factor; D006152:Cyclic GMP